Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,293
Total Claims
$2.4M
Drug Cost
884
Beneficiaries
$2,680
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+207%
Opioid rate vs peers
7.9% vs 2.6% avg
+151%
Cost per patient vs peers
$2,680 vs $1,068 avg
+57%
Brand preference vs peers
14.1% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid rate is 207% above Family Practice peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
7.9%
Opioid Rate
1,447
Opioid Claims
$54K
Opioid Cost
5.7%
Long-Acting Rate
Brand vs Generic
Brand: 2,559 claims · $2.0M
Generic: 15,605 claims · $344K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 147 | $219K |
| Tirzepatide | 144 | $184K |
| Apixaban | 179 | $173K |
| Rivaroxaban | 85 | $108K |
| Sitagliptin Phosphate | 81 | $80K |
| Dulaglutide | 47 | $73K |
| Fluticasone/Umeclidin/Vilanter | 71 | $72K |
| Empagliflozin | 58 | $69K |
| Mirabegron | 79 | $64K |
| Pimavanserin Tartrate | 12 | $60K |
| Dapagliflozin Propanediol | 34 | $52K |
| Finerenone | 37 | $51K |
| Linaclotide | 45 | $46K |
| Insulin Degludec | 53 | $41K |
| Umeclidinium Brm/Vilanterol Tr | 57 | $36K |
Prescribing Profile
Patient Profile
72
Avg Age
64%
Female
1.72
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data